SPI Infoamtion

このレポートは章ごとの個別販売も行っておりますのでお問い合わせ下さい。
※全てPDFでの販売となります。

Chapter-1: SUMMARY

SUMMARY
SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS)
SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS)

Chapter-2: OVERVIEW

DEFINITIONS
THE LIVER
LIVER FUNCTIONS
Metabolism
Drug Disposition
Bile Formation
Other Functions
COMMON SYMPTOMS OF LIVER DISEASE
Jaundice
Cholestasis
Liver Enlargement
Ascites
Portal Hypertension
Liver Encephalopathy
Liver Failure
Other Common Symptoms
LIVER DISEASES
TABLE 1 TYPES OF LIVER DISEASES
VIRUS-INDUCED LIVER DISEASE
Acute Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Chronic Hepatitis
Alcohol-induced Chronic Hepatitis
Chronic Active Hepatitis
Chronic Persistent Hepatitis
LIVER TUMORS
Benign Liver Tumors
Hepatocellular Adenoma
Hemangioma
Malignant Liver Tumors
Hepatocellular Carcinoma
Metastatic Liver Cancer
CONGENITAL LIVER DEFECTS
Biliary Atresia
Choledochal Cyst
AUTOIMMUNE LIVER DISORDERS
Hemochromatosis
Wilson’s Disease
Autoimmune Hepatitis
ALCOHOL-INDUCED LIVER DISEASE
Fatty Liver
Alcoholic Hepatitis
Alcoholic Cirrhosis
CHRONIC LIVER DISEASE
Cirrhosis
Fibrosis
NON-ALCOHOLIC FATTY LIVER

Chapter-3: REGULATORY ISSUES

TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005--2008
TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005--2008
FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005--2008
TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005--2008
TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005--2008

Chapter-4: PREVELANCE

UNITED STATES
UNITED KINGDOM
REST OF THE WORLD
PREVELANCE OF A FEW LIVER DISEASES
HEPATITIS
United States
TABLE 6 HEPATITIS BURDEN IN THE UNITED STATES (2005--2006)
TABLE 7 INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES (2006)
CIRRHOSIS
LIVER CANCER OR HEPATOCELLULAR CARCINOMA
NON-ALCOHOLIC FATTY LIVER

Chapter-5: CLASSIFICATION OF THERAPIES BY DISEASE

VIRUS-INDUCED LIVER DISEASE/HEPATITIS
VIRAL VACCINES
TABLE 8 VACCINES FOR HEPATITIS A PREVENTION
TABLE 9 VACCINES FOR HEPATITIS B PREVENTION
ANTIVIRAL DRUGS
Nucleoside Analogs
TABLE 10 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
Nucleotide Analogs
TABLE 11 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
TABLE 12 PROTEASE INHIBITORS USED TO TREAT HEPATITIS
INTERFERON
TABLE 13 INTERFERONS USED TO TREAT HEPATITIS
IMMUNE GLOBULINS
TABLE 14 IMMUNE GLOBULINS USED TO TREAT HEPATITIS
LIVER TUMORS/ LIVER CANCER
CHEMOTHERAPEUTIC DRUGS
TABLE 15 CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCER
TARGETED THERAPY
TABLE 16 TARGETED THERAPY USED TO TREAT LIVER CANCER
CONGENITAL LIVER DEFECTS
AUTOIMMUNE LIVER DISORDERS
TABLE 17 DRUGS USED TO TREAT WILSON’S DISEASE
CORTICOSTEROIDS
TABLE 18 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
IMMUNOSUPPRESSIVE AGENTS
TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
ANTIMETABOLITES
TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
ALCOHOL-INDUCED LIVER DISEASE
ANABOLIC STEROIDS
TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
ALCOHOL ABUSE DRUGS
TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
CHRONIC LIVER DISEASE
ANTI-REJECTION MEDICATION
TABLE 23 ANTI-REJECTION MEDICATIONS
ANTI-INFECTIVES
TABLE 24 ANTI-INFECTIVES
ANTIFUNGAL PROPHYLAXIS
TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
NON-ALCOHOLIC FATTY LIVER
GALLSTONE SOLUBILIZING AGENTS
TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
OTHER DRUGS
TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

Chapter-6: INDUSTRY STRUCTURE

HEPATITIS
HEPATITIS VACCINE
TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
NUCLEOSIDE ANALOGS
TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
NUCLEOTIDE ANALOGS
TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%)
FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY MANUFACTURER, 2008 (%)
INTERFERONS
TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
IMMUNE GLOBULINS
TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
LIVER TUMORS
CHEMOTHERAPY
TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
TARGETED THERAPY
TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
AUTOIMMUNE DISEASES
CHELATING AGENTS
TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
CORTICOSTEROIDS
TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
IMMUNOSUPPRESSIVE AGENTS
TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 11 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
ANTIMETABOLITES
TABLE 38 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 12 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
ALCOHOL-INDUCED LIVER DISEASES
ANABOLIC STEROIDS
TABLE 39 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 13 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
ALCOHOL ABUSE DRUGS
TABLE 40 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 14 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
CHRONIC LIVER DISEASE
ANTI-REJECTION MEDICATION
TABLE 41 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 15 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
ANTI-INFECTIVES
TABLE 42 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 16 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
ANTIFUNGAL PROPHYLAXIS
TABLE 43 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 17 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
NON-ALCOHOLIC FATTY LIVER DISEASE
GALLSTONE STABILIZING AGENTS
TABLE 44 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 18 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
OTHER DRUGS
TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)

Chapter-7: DEMAND AND USE

LIFE EXPECTANCY
LACK OF KNOWLEDGE
LACK OF TREATMENT OPTIONS
INCREASING NUMBER OF PATIENTS
RESEARCH AND DEVELOPMENT
INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS

Chapter-8: MARKET ANALYSIS

TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
HEPATITIS
MARKET SIZE
TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
MARKET OVERVIEW
LIVER TUMORS
MARKET SIZE
TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
MARKET OVERVIEW
AUTOIMMUNE DISEASES
MARKET SIZE
TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
MARKET OVERVIEW
ALCOHOL-INDUCED LIVER DISEASE
MARKET SIZE
TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS)
MARKET OVERVIEW
CHRONIC LIVER DISEASES
MARKET SIZE
TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS)
MARKET OVERVIEW
NON-ALCOHOLIC FATTY LIVER DISEASE
MARKET SIZE
TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS)
MARKET OVERVIEW

Chapter-9: DRUG-INDUCED LIVER DISEASE

DRUG-INDUCED
DRUGS THAT CAN CAUSE LIVER DISEASE
ACETAMINOPHEN (TYLENOL)
STATINS
NICOTINIC ACID (NIACIN)
AMIODARONE (CORDARONE)
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
METHOTREXATE (RHEUMATREX, TREXALL)
ANTIBIOTICS
TACRINE (COGNEX)
DISULFIRAM
VITAMIN SUPPLEMENTS
TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE

Chapter-10: NEW DEVELOPMENTS

CLINICAL TRIALS
TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
NEW DEVELOPMENTS
STEM CELL RESEARCH

Chapter-11: MARKET BY DRUG TYPE

MARKET SIZE
TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS)
MARKET SHARE
TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%)
VACCINES
MARKET SIZE
TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE,THROUGH 2014 ($ MILLIONS)
FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS)
ANTIVIRALS
MARKET SIZE
TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
INTERFERONS
MARKET SIZE
TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
IMMUNE GLOBULINS
MARKET SIZE
TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
CHEMOTHERAPY
MARKET SIZE
TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
TARGETED THERAPY
MARKET SIZE
TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS)
CHELATING AGENTS
MARKET SIZE
TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
CORTICOSTEROIDS
MARKET SIZE
TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
IMMUNOSUPPRESSIVE AGENTS
MARKET SIZE
TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
ANTIMETABOLITES
MARKET SIZE
TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
ANABOLIC STEROIDS
MARKET SIZE
TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
ALCOHOL ABUSE DRUGS
MARKET SIZE
TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS)
ANTI-REJECTION MEDICATION
MARKET SIZE
TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
INFECTION-FIGHTING DRUGS
MARKET SIZE
TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS)
ANTIFUNGAL PROPHYLAXIS
MARKET SIZE
TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS)
GALLSTONE SOLUBILIZING AGENTS
MARKET SIZE
TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS)
OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES
MARKET SIZE
TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)

Chapter-12: PATENT ANALYSIS

CHAPTER 13: PATENT ANALYSIS
PATENTS BY YEAR
TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005--2009
FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005--2009
PATENTS BY TYPE
TABLE 82 NUMBER OF PATENTS BY TYPE, 2005--2009
FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005--2009
FIGURE 49 PATENTS, SHARE BY TYPE, 2005--2009 (%)
PATENTS BY COUNTRY
TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005--2009
FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005--2009
PATENTS BY COMPANY
TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005--2009
FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005--2009
PATENTS BY ASSIGNEE
TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005--2009
FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005--2009

Chapter-13: COMPANY PROFILES

ABBOTT LABORATORIES
ACTAVIS U.S.
ALKERMES, INC
ALNYLAM PHARMACEUTICALS
BARR PHARMACEUTICALS
BAYER SCHERING PHARMA AG
BIOTEST PHARMACEUTICALS CORPORATION
BRISTOL-MYERS SQUIBB
CANGENE CORPORATION
DEBIOPHARM GROUP
ELI LILLY & COMPANY
GALMED MEDICAL RESEARCH, LTD.
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
HUMAN GENOME SCIENCES
IDENIX PHARMACEUTICALS INC.
KINEMED, INC.
MALLINCKRODT
MEDA PHARMACEUTICALS
MERCK & CO.
NOVARTIS AG
PAR PHARMACEUTICAL COMPANIES, INC.
ROCHE
ROXANE LABORATORIES, INC.
SANOFI AVENTIS
SAVIENT PHARMACEUTICALS, INC.
SCHERING-PLOUGH
SCYNEXIS
TEVA PHARMACEUTICAL INDUSTRIES LTD.
THREE RIVERS PHARMACEUTICALS
VALEANT PHARMACEUTICALS INTERNATIONAL
WATSON PHARMACEUTICALS, INC.
WYETH INC.
ZYDUS PHARMACEUTICALS INC.
ZYMOGENETICS
APPENDIX
ABBREVIATIONS